Clinical trials: Botox
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive…
- Trial name
- NCT02590250
- Testing
- botulinum toxin Type A
- Where
- 12 sites in India
- Volunteers
- 250 people
- Sponsor
- Allergan
Muscle Spasticity
BOTOX® Economic Spasticity Trial (BEST)
This is a study to investigate if patients who have had a stroke and suffer from spasticity might benefit from being given BOTOX® in addition to the normal Standard Care.
- Trial name
- NCT00549783
- Testing
- Botulinum Toxin Type A 900kD
- Where
- 4 sites in Canada, Germany and 2 more
- Volunteers
- 274 people
- Sponsor
- Allergan
Migraine Disorders
A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine
This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.
- Trial name
- NCT02147561
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Allergan
Overactive Bladder
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910845
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 2 sites in United States, Canada
- Volunteers
- 557 people
- Sponsor
- Allergan
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Chronic Migraine, Headache
Open Label, 6-month Study for High Frequency and Chronic Migraine,
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published…
- Trial name
- NCT06133491
- Testing
- Daxibotulinumtonix A
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ki Health Partners. LLC
Skin Aging
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
- Trial name
- NCT01940991
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Revance Therapeutics, Inc.
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Upper Limb Spasticity
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
- Trial name
- NCT06783114
- Testing
- Recombinant Botulinum Toxin Type A for injection (YY001), BOTOX®
- Where
- 24 sites in China
- Volunteers
- 254 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Spasticity
Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA
The aim of the study is to describe the long-term use of abobotulinumtoxinA (Dysport®) in adult subjects affected with upper limb spasticity (ULS) +/- lower limb spasticity (LLS) who received treatment with Dysport® for a minimum…
- Trial name
- RETURN (NCT04446702)
- Where
- Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ipsen
Interstitial Cystitis, IC
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
The investigators believe that this study is of importance of several aspects: 1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode. 2.
- Trial name
- NCT01997983
- Testing
- TC-3 Gel mixed with Botox (BTX)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- UroGen Pharma Ltd.
Essential Tremor of the Upper Limbs
Botulinum Toxin A to Treat Arm Tremor
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
- Trial name
- NCT02207946
- Testing
- IncobotulinumtoxinA
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Merz Pharmaceuticals GmbH
Upper and/or Lower Limb Focal Spasticity
A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity
The aim of this retrospective study is to describe the real-world outcomes with the treatment of adult patients with Dysport® injections for focal upper limb spasticity (ULS) and/or focal lower limb spasticity (LLS) in NHS…
- Trial name
- DYSCOVER (NCT04604379)
- Where
- 3 sites in United Kingdom
- Volunteers
- 123 people
- Sponsor
- Ipsen
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy
- Trial name
- NCT01603641
- Testing
- Botulinum Toxin Type A
- Where
- 56 sites in United States, Hungary and 7 more
- Volunteers
- 370 people
- Sponsor
- Allergan
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT00156910
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 679 people
- Sponsor
- Allergan
Cerebral Palsy, Muscle Spasticity
Dysport® Pediatric Lower Limb Spasticity Study
The purpose of this research study is to determine whether Dysport® is effective in the treatment of increased stiffness of the calf muscles and to evaluate the safety of this treatment in children with Cerebral Palsy.
- Conditions
- Cerebral Palsy, Muscle Spasticity, Children
- Trial name
- NCT01249417
- Testing
- Botulinum toxin type A
- Where
- 29 sites in United States, Chile and 4 more
- Volunteers
- 241 people
- Sponsor
- Ipsen
Moderate to Severe Glabellar Lines
A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines
The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines.
- Trial name
- NCT06481475
- Testing
- YY003, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 153 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Skin Aging
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)
- Trial name
- NCT00856414
- Testing
- botulinum toxin Type A
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Allergan
Glabellar Frown Lines
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
- Trial name
- NCT03004248
- Testing
- Botulinum Toxins, Type A
- Where
- 61 sites in United States, Canada
- Volunteers
- 2,691 people
- Sponsor
- Revance Therapeutics, Inc.